Cognition Therapeutics (CGTX) Insider Trading & Ownership $0.45 0.00 (0.00%) (As of 12/17/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Cognition Therapeutics (NASDAQ:CGTX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage20.75%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$9,975.00Number OfInsiders Selling(Last 12 Months)0 Get CGTX Insider Trade Alerts Want to know when executives and insiders are buying or selling Cognition Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CGTX Insider Buying and Selling by Quarter Ad Crypto 101 MediaDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Claim your FREE book now before it's too late! Cognition Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails3/14/2024Lisa RicciardiCEOBuy5,700$1.75$9,975.00 (Data available from 1/1/2013 forward) CGTX Insider Trading Activity - Frequently Asked Questions Who is on Cognition Therapeutics's Insider Roster? The list of insiders at Cognition Therapeutics includes Ellen B Richstone, Lisa Ricciardi, and Peggy Wallace. Learn more on insiders at CGTX. What percentage of Cognition Therapeutics stock is owned by insiders? 20.75% of Cognition Therapeutics stock is owned by insiders. Learn more on CGTX's insider holdings. Which Cognition Therapeutics insiders have been buying company stock? The following insider purchased CGTX shares in the last 24 months: Lisa Ricciardi ($9,975.00). How much insider buying is happening at Cognition Therapeutics? Insiders have purchased a total of 5,700 CGTX shares in the last 24 months for a total of $9,975.00 bought. Cognition Therapeutics Key ExecutivesMs. Lisa Ricciardi (Age 64)CEO, President & Director Compensation: $854.15kMr. John Brendan Doyle (Age 47)Chief Financial Officer Compensation: $414.88kDr. Anthony O. Caggiano M.D. (Age 54)Ph.D., Chief Medical Officer and Head of R&D Compensation: $616.27kDr. Steven A. Weissman Ph.D.VP & Head of CMC More Insider Trading Tools from MarketBeat Related Companies Eliem Therapeutics Insider Buying Generation Bio Insider Buying Werewolf Therapeutics Insider Buying Ovid Therapeutics Insider Buying FibroBiologics Insider Buying Aerovate Therapeutics Insider Buying ESSA Pharma Insider Buying Unicycive Therapeutics Insider Buying ZIVO Bioscience Insider Buying Repare Therapeutics Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles AppLovin Insiders Sell Shares: Stock Price Indicated Higher Are 2024’s Top Insider Buys a Good Bet for 2025? Bargains Galore? 3 Stocks With Insider Buying in the MillionsInsiders Keep Buying These Stocks: 2 to Buy, 1 to AvoidZeta Global Holdings Insiders Buy Stock After Short-Report This page (NASDAQ:CGTX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cognition Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cognition Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
